Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Game changer for arthritis and anti-fibrosis drugs

12.11.2012
Discovery shows medications can treat inflammation without increasing risk for infection

In a discovery that can fundamentally change how drugs for arthritis, and potentially many other diseases, are made, University of Utah medical researchers have identified a way to treat inflammation while potentially minimizing a serious side effect of current medications: the increased risk for infection.

These findings provide a new roadmap for making powerful anti-inflammatory medicines that will be safer not only for arthritis patients but also for millions of others with inflammation-associated diseases, such as diabetes, traumatic brain injury, and inflammatory bowel disease, according to cardiologist Dean Y. Li, M.D., Ph.D., the U School of Medicine vice dean for research and HA and Edna Benning endowed professor of medicine who led the study. "This can change the way medication is made," he says. "If we can find a way to replace our most powerful drugs for arthritis, we might be able to develop another way to treat inflammation in other diseases that we've been unable to touch because of the danger of suppressing people's immune systems."

The research, funded by the National Institutes of Health (NIH) and published Sunday, Nov. 11, 2012, Nature online, provides the University the opportunity to explore commercializing the technology either through collaboration outside of the state with pharmaceutical companies or within the state via initiatives such as USTAR. The Utah Legislature established USTAR (Utah Science Technology and Research) initiative in 2006 to promote economic growth and high paying jobs through research at the U of U and Utah State University.

"This is just one example of many scientific opportunities for the University and USTAR to work together to benefit not only millions of patients but build medical innovations in Utah," says Li, who's also director of the U of U Molecular Medicine program.

Two Cellular Pathways

When the body undergoes trauma or gets an infection, it responds by releasing cytokines—proteins that enter cells and unleash a three-pronged attack to kill invading bugs, hype up the immune system, and cause inflammation. While inflammation fights infection, it also produces an undesired side effect by weakening blood vessels, which can lead to swelling in the joints, brain or other areas. Scientists long have believed that cytokines use one cellular pathway in their response to infection, meaning that drugs made to block cytokines from causing inflammation also block the immune system and the ability to kill invading bugs.

In a study with mice, Li and his research colleagues upended the one-pathway belief by showing that cytokines use not one but two cellular pathways to battle infection: one to turn on the immune system and kill intruders and a separate one that destroys the architecture of tissues and organs. Identifying the separate pathway for inflammation has vast potential for developing drugs. "We can selectively block inflammation without making the patient immunosuppressed," Li says. "This rewrites the strategy for today's medicines. We focused the work on arthritis given this is a proven market for drugs that reduce damage from inflammation and fibrosis, but we suspect that many other diseases ranging from fibrosis following heart attacks to inflammatory bowel disease may benefit from such an approach."

Li's discovery has dramatic implications for the field of rheumatology, according to Tracy M. Frech, M.D., U of U assistant professor of internal medicine who specializes in rheumatology. "This may lead to more effective treatments for conditions such as lupus, systemic sclerosis, and the spectrum of inflammatory arthritis, without putting patients at risk for infections," she says. "This phenomenal work is a credit to the strong molecular medicine program here at the University of Utah."

Before a new generation of anti-inflammation drugs can be made, researchers must screen for molecules of chemical compounds that can be turned in pharmaceutical-grade drugs, something the University can and should do, according to Li. This can be accomplished either through collaboration with pharmaceutical companies outside of the state or with sources inside Utah, such as the USTAR initiative.

This study was funded by NIH grants:

#R01HL068873
#R01HL077671
#U54AI065357

Phil Sahm | EurekAlert!
Further information:
http://www.hsc.utah.edu

More articles from Health and Medicine:

nachricht World first: Massive thrombosis removed during early pregnancy
20.07.2017 | Universitätsspital Bern

nachricht Therapy of preterm birth in sight?
19.07.2017 | Universitätsspital Bern

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

Im Focus: On the way to a biological alternative

A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes

The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....

Im Focus: The 1 trillion tonne iceberg

Larsen C Ice Shelf rift finally breaks through

A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...

Im Focus: Laser-cooled ions contribute to better understanding of friction

Physics supports biology: Researchers from PTB have developed a model system to investigate friction phenomena with atomic precision

Friction: what you want from car brakes, otherwise rather a nuisance. In any case, it is useful to know as precisely as possible how friction phenomena arise –...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Closing the Sustainability Circle: Protection of Food with Biobased Materials

21.07.2017 | Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

 
Latest News

NASA looks to solar eclipse to help understand Earth's energy system

21.07.2017 | Earth Sciences

Stanford researchers develop a new type of soft, growing robot

21.07.2017 | Power and Electrical Engineering

Vortex photons from electrons in circular motion

21.07.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>